Evidence map›Paper›PMID 22944725›Full record

Trial reportJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2013

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Michael Anstead, Sonya L Heltshe, Umer Khan, Joseph T Barbieri, Markus Langkamp, Gerd Döring, Shimoni Dharia, Ronald L Gibson, Miriam M Treggiari, James Lymp and 2 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 6 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 6 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.The Cochrane database of systematic reviews · 2018
    Pooled it
  5. Pooled it
  6. Oral anti-pseudomonal antibiotics for cystic fibrosis.The Cochrane database of systematic reviews · 2016
    Pooled it
  7. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
    Trial
  8. Science translational medicine · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Michael AnsteadDepartment of Pediatrics, University of Kentucky, Lexington KY 40563-0284, USA. Electronic address: mianst0@uky.edu.
Sonya L HeltsheSeattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
Umer KhanSeattle Children's Research Institute, Seattle WA 98121, USA.
Joseph T BarbieriMicrobiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee WI 53226, USA.
Markus LangkampMediagnost®, Aspenhaustr. 25, 72770 Reutlingen, Germany.
Gerd DöringUniversitätsklinikum Tübingen, Institut für Medizinische Mikrobiologie und Hygiene, Wilhelmstr. 31, 72074 Tübingen, Germany.
Shimoni DhariaDepartment of Pediatric Pulmonology, Children's Hospital of Wisconsin, Milwaukee WI, 53226, USA.
Ronald L GibsonSeattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
Miriam M TreggiariDepartment of Anesthesiology and Pain Medicine, Seattle Children's Hospital, Seattle WA 98104, USA.
James LympSeattle Children's Research Institute, Seattle WA 98121, USA.
Margaret RosenfeldSeattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
Bonnie RamseySeattle Children's Hospital and University of Washington School of Medicine, Seattle WA 98105-0371, USA.
Seattle Children's Hospital · USChildren's Hospital of Wisconsin · USImmundiagnostik (Germany) · DEMedical College of Wisconsin · USUniversitätsklinikum Tübingen · DEUniversity of Kentucky · US

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Mechanisms of Bacterial Toxin ActionR01AI030162 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T · 1990 to 2019
$6.7M
Early Antipseudomonal Therapy in Cystic FibrosisU01HL080310 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI RAMSEY, BONNIE W · 2004 to 2008
$6.5M
NHLBI NIH HHS NIH U01 HL80310NHLBI NIH HHS U01 HL080310NIAID NIH HHS NIH-R01 AI30162NIAID NIH HHS R01 AI030162NIDDK NIH HHS NIH P30 DK089507NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

backgroundThe prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.

methodsUsing five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.

resultsBaseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation.

conclusionP. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.

Indexed as

Anti-Bacterial AgentsBacteriological TechniquesChildCystic FibrosisEnzyme-Linked Immunosorbent AssayFemaleHumansMalePrognosisPseudomonas aeruginosaPseudomonas InfectionsRecurrenceRisk FactorsSerologic TestsAnti-Bacterial Agents

Identifiers

PMID22944725
PMCPMC3696392
OpenAlexW2033895820

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.